Elicio Therapeutics, Inc. (ELTX) Stock

About Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.

Elicio Therapeutics, Inc. is led by CEO Robert T. Connelly, employs 32 people, headquartered in US, publicly traded since 2021.

Elicio Therapeutics, Inc. (ELTX) stock trades at $3.01 with a market capitalization of $57.29M. The stock is valued at a price-to-earnings (P/E) ratio of -1.27, price-to-book of -38.02, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.66 and $16.00, and currently trades 81.2% below its 52-week high.

On profitability, Elicio Therapeutics, Inc. generates a return on equity (ROE) of -977.67%, return on capital employed of -243.08%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: elicio.com